Clinical outcome of gastric cancer patients with bone marrow metastases
| Autor: | Hyo Song Kim, Hee Jin Kim, Seong Yoon Yi, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Young-Hyeh Ko, Junho Jang, Jeeyun Lee, Won Ki Kang, Hyun Jung Jun |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Bone Neoplasms Adenocarcinoma Metastasis Bone Marrow Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Humans Stomach cancer Survival rate Aged Retrospective Studies Bone cancer business.industry Liver Neoplasms Bone metastasis Cancer General Medicine Middle Aged medicine.disease Prognosis humanities Surgery body regions Survival Rate medicine.anatomical_structure Treatment Outcome Bone marrow neoplasm Lymphatic Metastasis Female Bone marrow business Bone Marrow Neoplasms Carcinoma Signet Ring Cell |
| Zdroj: | Oncology. 73(3-4) |
| ISSN: | 1423-0232 |
| Popis: | Background: Gastric cancer with bone marrow metastases is known to pursue a rapidly deteriorating clinical course. We conducted a retrospective analysis to evaluate clinical manifestations and prognosis of gastric cancer patients with bone marrow metastases. Methods: Between September 1994 and February 2006, 39 gastric cancer patients with pathologically confirmed bone marrow dissemination were selected. Results: The majority of the patients showed younger age, poorly differentiated adenocarcinoma or signet ring cell carcinoma, thrombocytopenia, anemia, elevated lactate dehydrogenase and alkaline phosphatase. Poor prognostic factors for survival were serum sodium ≤133 mmol/l [relative risk (RR) 4.57; 95% CI 1.99–10.52; p < 0.001], the presence of lung metastasis (RR 3.47; 95% CI 1.48–8.15; p = 0.007) and the presence of peritoneal seeding (RR 2.17; 95% CI 1.06–4.43; p = 0.036). Median survival durations after bone marrow metastases for patients without any adverse factors (n = 19, 48.7%) and those with 1–3 adverse factors (n = 20, 51.3%) were 67 and 23 days, respectively (p = 0.013). Patients without any adverse factors did benefit from palliative chemotherapy (p = 0.048). Conclusion: We suggest that gastric cancer patients with bone marrow metastases should receive more tailored therapies according to different risk factors in order to enhance survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|